Somapacitan for treating idiopathic short stature or Noonan syndrome or small for gestational age in people aged 2 to 18 years

Somapacitan is in clinical development for the treatment of small for gestational age or Noonan syndrome or idiopathic short stature in patients aged 2 to 18 years. Idiopathic short stature is defined as shortness in childhood without a specific cause. This condition may be familial (run in families) or nonfamilial and may be associated with or without delay of puberty. Noonan syndrome is a genetic condition that can cause a wide range of distinctive features and health problems, including short stature. Small for gestational age describes newborn babies with a birth weight and/or length below the normal range for gestational age. Current treatment for growth disturbance in Noonan syndrome or children born small for gestational age whose growth has not caught up by 4 years or later involves daily growth hormone injections that can be burdensome for patients and caregivers. There is no approved growth hormone for idiopathic short stature.